China’s National Medical Products Administration (NMPA) said on March 13 that it has approved Boruikang Medical (Shanghai) Co.’s implantable brain–computer interface (BCI) hand motor function compensation system, the first invasive BCI medical device to receive market approval globally. The system combines epidural electrodes, an implanted transmitter, external software, and a pneumatic glove to translate neural signals into hand‑grip assistance for patients with C2–C6 cervical spinal cord injury. The approval, following 36 clinical procedures including multicenter confirmatory trials, marks a shift in China from invasive BCI experiments to regulated clinical use.
According to the NMPA’s announcement, the product was registered as an innovative medical device and is designed for patients with tetraplegia caused by cervical spinal cord injury at the C2–C6 level. The full system includes an implant, electrodes, a transceiver, external software, and a pneumatic glove, forming a closed loop that collects neural signals, decodes intent, and produces assisted hand movements. This description makes it clear the device is positioned as a functional compensation tool rather than a full neuroprosthetic replacement, which matters for how clinicians frame expected outcomes and rehabilitation pathways.
Clinical reporting underscores the scope of testing that preceded approval. Cailian Press cited 36 total procedures, including four feasibility cases and 32 cases from a multicenter confirmatory study. Those trials were carried out in patients with severe cervical spinal cord injury, and the reported outcome focus was the recovery of hand‑grip capability through assisted motion. The size and structure of the trials are notable for a novel implantable neurotechnology in China, signaling that regulators required a multi‑center data set before allowing commercial clinical use.
Chinese media coverage repeatedly framed the approval as a “world’s first,” highlighting the rarity of invasive BCI devices reaching the market. China Economic Net and 21st Century Business Herald both reported the NMPA decision as a global first for invasive BCI medical devices, positioning the approval as a milestone not only for a single company but for the country’s medical‑device innovation pipeline. That framing reflects China’s push to move advanced neurotechnology from research labs into regulated, reimbursable clinical products. China has also outlined a 3–5 year horizon for broader public use of BCI, according to a recent BCI timeline update.
The product’s technical design—epidural implantation rather than deeper intracortical placement—also signals a pragmatic pathway for first‑generation clinical adoption. The NMPA summary states that the device uses a minimally invasive approach outside the dura, with signal acquisition, decoding, and assisted actuation through a pneumatic glove. That architecture lowers surgical complexity relative to deeper implants while still qualifying as invasive BCI, and it maps to a near‑term clinical goal: enabling basic grasping and hand function in patients with high‑level spinal cord injury.
The patient segment is medically significant and commercially defined. Cervical spinal cord injury at the C2–C6 level often results in tetraplegia and loss of hand control, which dramatically limits independence in daily activities. A system that can restore even partial grasping function has direct quality‑of‑life implications and may reduce the long‑term burden on caregivers. From a clinical perspective, that makes the approval more than symbolic; it targets a clearly defined, high‑need population rather than a broad, undefined BCI market.
Industry data suggests that this regulatory milestone arrives as China’s BCI market is expanding. People’s Daily Finance cited CCID Consulting estimates that China’s BCI market reached 3.2 billion yuan in 2024 and could grow to 6.14 billion yuan by 2028, implying a compound annual growth rate of about 17.7%. That growth projection provides economic context for why regulators and companies are pushing toward commercialization: the market is still small but is expected to scale rapidly if clinical products can demonstrate real‑world utility.
For the broader industry chain, a commercial invasive BCI device creates demand across multiple layers of the ecosystem: biocompatible materials, electrode manufacturing, signal‑processing algorithms, and rehabilitation hardware such as assistive gloves. The Boruikang system’s architecture ties together implantables and external devices, suggesting that value capture will be distributed across hardware, software, and clinical services. If hospitals begin adopting the system, suppliers in each of these areas could see early revenue signals, which could in turn attract more investment into the BCI supply chain.
At the same time, commercialization raises practical questions that will determine scale. Hospitals will need surgical training, post‑implant monitoring protocols, and rehabilitation workflows to integrate the system into standard care. Pricing, reimbursement, and long‑term safety data will be key for adoption decisions, especially for a patient population that often requires ongoing, multi‑year care. These factors will shape whether the approval becomes a niche milestone or a trigger for broader clinical adoption. It also lands amid China’s broader AI industrial policy push, including the 15th Five‑Year Plan focus on AI+.
What changed is that China’s regulator approved an invasive BCI medical device with defined indications and clinical evidence, moving the category from experimental trials to regulated clinical use. What may happen next is an acceleration of clinical deployments, supplier readiness, and policy attention, as hospitals test the system’s real‑world outcomes and the industry gauges whether China can turn a “world’s first” approval into a scalable medical‑device market.
Sources
- https://www.nmpa.gov.cn/zhuanti/cxylqx/cxylqxlm/20260313134742156.html
- http://www.ce.cn/xwzx/gnsz/gdxw/202603/t20260314_2827413.shtml
- https://m.21jingji.com/article/20260313/herald/dad1c4a9bcb18271485e2f9e660f5fbf_zaker.html
- https://www.cls.cn/detail/2312030
- http://finance.people.com.cn/n1/2026/0106/c1004-40639817.html
